PTC Therapeutics, Inc. (PTCT)
| Market Cap | 6.11B +56.4% |
| Revenue (ttm) | 827.11M -53.3% |
| Net Income | -186.73M |
| EPS | -2.32 |
| Shares Out | 82.95M |
| PE Ratio | n/a |
| Forward PE | 37.83 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,836,349 |
| Open | 74.07 |
| Previous Close | 64.49 |
| Day's Range | 69.43 - 79.91 |
| 52-Week Range | 39.53 - 87.50 |
| Beta | 0.53 |
| Analysts | Buy |
| Price Target | 84.93 (+15.25%) |
| Earnings Date | May 7, 2026 |
About PTCT
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for PTCT stock is "Buy." The 12-month stock price target is $84.93, which is an increase of 15.25% from the latest price.
News
PTC Therapeutics price target raised to $94 from $92 at Morgan Stanley
Morgan Stanley analyst Judah Frommer raised the firm’s price target on PTC Therapeutics (PTCT) to $94 from $92 and keeps an Overweight rating on the shares.
PTC Therapeutics upgraded to Buy from Hold at TD Cowen
TD Cowen upgraded PTC Therapeutics (PTCT) to Buy from Hold with a price target of $90, up from $75. The company’s 2026 product revenue guidance was raised on the back
PTC Therapeutics reports Q1 EPS (3c) vs. ($10.04) last year
Reports Q1 revenue $273M, consensus $225.35M. “We are off to a strong start to 2026 with outstanding revenue performance this quarter that supports raising our full-year product revenue guidance,” sai...
PTC Therapeutics raises 2026 revenue view to $1.08B-$1.18B, consensus $990.78M
16:10 EDT PTC Therapeutics (PTCT) raises 2026 revenue view to $1.08B-$1.18B, consensus $990.78M
PTC Therapeutics Earnings Call Transcript: Q1 2026
Record Q1 revenue driven by Sephience's strong global launch led to raised 2026 guidance. U.S. remains the main growth driver, with international expansion accelerating and robust payer coverage supporting broad adoption.
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
– First quarter 2026 total revenue of $273 million, including $226 million of product revenue, supporting full-year 2026 guidance raise – – Global Sephience™ (sepiapterin) launch momentum continues...
PTC Therapeutics to Participate in Upcoming Investor Conferences
WARREN, N.J., May 4, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: Bank of America Securities Health Care Conf...
PTC Therapeutics Transcript: Study result
Votoplam demonstrated dose-dependent slowing of Huntington's disease progression over 24 months, with a favorable safety profile and no NfL spikes. These results support the ongoing phase III INVEST-HD trial in early symptomatic patients and potential regulatory discussions.
PTC Therapeutics reports ‘positive’ results from PIVOT-HD study
PTC Therapeutics (PTCT) reported positive topline results from the 24-month interim analysis of the PIVOT-HD long-term extension study, with favorable dose-dependent effects on disease progression for...
PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam
- Dose-dependent benefit on cUHDRS in Stage 2 participants compared to matched natural history cohort, with 52% slowing at 10 mg dose - - Continued evidence of favorable safety profile - - Novartis i...
PTC Therapeutics to Report Results from PIVOT-HD Long Term Extension Study
WARREN, N.J., April 28, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webcast conference call today, April 28 at 4:30 p.m.
PTC Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026
WARREN, N.J., April 22, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its first quarter 2026 financial resul...
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WARREN, N.J., April 17, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 13, 2026, the company approved non-statutory stock options to purchase an aggregate of ...
PTC Therapeutics initiated with an Outperform at Raymond James
Raymond James analyst Tiago Fauth last night initiated coverage of PTC Therapeutics (PTCT) with an Outperform rating and $108 price target PTC is commercializing Sephience, the first and only phenylke...
PTC Therapeutics initiated with an Outperform at Raymond James
Raymond James initiated coverage of PTC Therapeutics (PTCT) with an Outperform rating and $108 price target
PTC Therapeutics price target lowered to $81 from $82 at RBC Capital
RBC Capital analyst Brian Abrahams lowered the firm’s price target on PTC Therapeutics (PTCT) to $81 from $82 and keeps a Sector Perform rating on the shares as part of
PTC Therapeutics assumed at Hold from Buy at Jefferies
Jefferies downgraded PTC Therapeutics (PTCT) to Hold from Buy with a price target of $76, down from $91, as the analyst took over coverage of the stock. The story has
PTC Therapeutics Appoints Biotech Banking Pioneer Jessica Chutter to Board of Directors
WARREN, N.J., March 25, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced the appointment of Jessica Chutter to its Board of Directors.
PTC Therapeutics Transcript: Barclays 28th Annual Global Healthcare Conference
Sepiapterin’s launch for PKU has seen rapid adoption, strong early revenues, and broad patient benefit, with global expansion underway and low discontinuation rates. The pipeline is advancing, notably in Huntington’s disease, with multiple early-stage programs moving toward the clinic.
PTC Therapeutics Transcript: Leerink Global Healthcare Conference 2026
Sephience's global launch for PKU exceeded expectations, with broad patient uptake, high adherence, and strong financial performance. The pipeline is advancing with new formulations, ongoing studies, and promising programs in FA and HD, while the company pursues both internal development and strategic partnerships.
PTC Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Sephience's global launch drove rapid revenue growth and broad patient adoption, with strong financial performance and disciplined expense management positioning the company for cash flow break even in 2026. Pipeline progress includes late-stage Huntington's and Friedreich's ataxia programs, while early-stage R&D and global expansion remain key priorities.
PTC Therapeutics to Participate at Upcoming Investor Conferences
WARREN, N.J., Feb. 23, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: TD Cowen 46th Annual Health Care Conferen...
PTC Therapeutics price target raised to $92 from $90 at Morgan Stanley
Morgan Stanley raised the firm’s price target on PTC Therapeutics (PTCT) to $92 from $90 and keeps an Overweight rating on the shares. The firm updated its model for actuals
PTC Therapeutics price target raised to $120 from $119 at Barclays
Barclays analyst Eliana Merle raised the firm’s price target on PTC Therapeutics (PTCT) to $120 from $119 and keeps an Overweight rating on the shares post the Q4 report. The
PTC Therapeutics price target raised to $82 from $78 at RBC Capital
RBC Capital analyst Brian Abrahams raised the firm’s price target on PTC Therapeutics (PTCT) to $82 from $78 and keeps a Sector Perform rating on the shares. The company’s pre-reported